Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant.

Neggers SJ, van Aken MO, de Herder WW, Feelders RA, Janssen JA, Badia X, Webb SM, van der Lely AJ

The Journal of clinical endocrinology and metabolism22 Jul 2008Cited by 123 (Europe PMC)

PMID18647806DOI10.1210/jc.2008-0669PepBankPUB-18647806

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialEfficacy outcome
In acromegalic patients on SSA therapy, AcroQoL improved after pegvisomant addition (P = 0.008).
In plain wordsIn acromegalic patients on SSA therapy, quality of life improved after pegvisomant addition compared with baseline.
Peptide
Pegvisomant
Outcome
Direction not reportedAcroQoL
Study
n = 20
Comparator
Baseline on SSA therapy
Outcome group
Quality of life · Whole body
Studied dose
40 mg weekly · 16 wkAs given in this study (human).
Source sentences
Summary
The AcroQoL (P = 0.008) and AcroQoL physical (P = 0.002) improved significantly after PEG-V was added.
2 context sentences(design, population, supporting numbers)
Summary · context
The objective of the study was to assess whether weekly administration of 40 mg pegvisomant (PEG-V) improves quality of life (QoL) and metabolic parameters in acromegalic patients with normal age-adjusted IGF-I concentrations during long-acting somatostatin analog (SSA) treatment.
Summary · context
Twenty acromegalic subjects received either PEG-V or placebo for two consecutive treatment periods of 16 wk, separated by a washout period of 4 wk. Efficacy was assessed as change between baseline and end of each treatment period.
Report a problemFND-1864780601
02HumanNon-randomized trialEfficacy outcome
In acromegalic patients on SSA therapy, physical AcroQoL improved after pegvisomant addition (P = 0.002).
In plain wordsIn acromegalic patients on SSA therapy, physical quality of life improved after pegvisomant addition compared with baseline.
Peptide
Pegvisomant
Outcome
Direction not reportedAcroQoL physical
Study
n = 20
Comparator
Baseline on SSA therapy
Outcome group
Quality of life · Whole body
Studied dose
40 mg weekly · 16 wkAs given in this study (human).
Source sentences
Summary
The AcroQoL (P = 0.008) and AcroQoL physical (P = 0.002) improved significantly after PEG-V was added.
2 context sentences(design, population, supporting numbers)
Summary · context
The objective of the study was to assess whether weekly administration of 40 mg pegvisomant (PEG-V) improves quality of life (QoL) and metabolic parameters in acromegalic patients with normal age-adjusted IGF-I concentrations during long-acting somatostatin analog (SSA) treatment.
Summary · context
Twenty acromegalic subjects received either PEG-V or placebo for two consecutive treatment periods of 16 wk, separated by a washout period of 4 wk. Efficacy was assessed as change between baseline and end of each treatment period.
Report a problemFND-1864780602
03HumanNon-randomized trialEfficacy outcome
In acromegalic patients on SSA therapy, PASQ improved after pegvisomant addition (P = 0.038).
In plain wordsIn acromegalic patients on SSA therapy, symptom scores improved after pegvisomant addition compared with baseline.
Peptide
Pegvisomant
Outcome
Direction not reportedPASQ
Study
n = 20
Comparator
Baseline on SSA therapy
Outcome group
Quality of life · Whole body
Studied dose
40 mg weekly · 16 wkAs given in this study (human).
Source sentences
Summary
The addition of PEG-V also significantly improved the PASQ (P = 0.038) and the single PASQ questions, perspiration (P = 0.024), soft tissue swelling (P = 0.036), and overall health status (P = 0.035).
2 context sentences(design, population, supporting numbers)
Summary · context
The objective of the study was to assess whether weekly administration of 40 mg pegvisomant (PEG-V) improves quality of life (QoL) and metabolic parameters in acromegalic patients with normal age-adjusted IGF-I concentrations during long-acting somatostatin analog (SSA) treatment.
Summary · context
Twenty acromegalic subjects received either PEG-V or placebo for two consecutive treatment periods of 16 wk, separated by a washout period of 4 wk. Efficacy was assessed as change between baseline and end of each treatment period.
Report a problemFND-1864780603
04HumanNon-randomized trialEfficacy outcome
In acromegalic patients on SSA therapy, perspiration scores improved after pegvisomant addition (P = 0.024).
In plain wordsIn acromegalic patients on SSA therapy, perspiration scores improved after pegvisomant addition compared with baseline.
Peptide
Pegvisomant
Outcome
Direction not reportedPerspiration
Study
n = 20
Comparator
Baseline on SSA therapy
Outcome group
Quality of life · Whole body
Studied dose
40 mg weekly · 16 wkAs given in this study (human).
Source sentences
Summary
The addition of PEG-V also significantly improved the PASQ (P = 0.038) and the single PASQ questions, perspiration (P = 0.024), soft tissue swelling (P = 0.036), and overall health status (P = 0.035).
2 context sentences(design, population, supporting numbers)
Summary · context
The objective of the study was to assess whether weekly administration of 40 mg pegvisomant (PEG-V) improves quality of life (QoL) and metabolic parameters in acromegalic patients with normal age-adjusted IGF-I concentrations during long-acting somatostatin analog (SSA) treatment.
Summary · context
Twenty acromegalic subjects received either PEG-V or placebo for two consecutive treatment periods of 16 wk, separated by a washout period of 4 wk. Efficacy was assessed as change between baseline and end of each treatment period.
Report a problemFND-1864780604
05HumanNon-randomized trialEfficacy outcome
In acromegalic patients on SSA therapy, soft tissue swelling scores improved after pegvisomant addition (P = 0.036).
In plain wordsIn acromegalic patients on SSA therapy, swelling scores improved after pegvisomant addition compared with baseline.
Peptide
Pegvisomant
Outcome
Direction not reportedSoft tissue swelling
Study
n = 20
Comparator
Baseline on SSA therapy
Outcome group
Quality of life · Whole body
Studied dose
40 mg weekly · 16 wkAs given in this study (human).
Source sentences
Summary
The addition of PEG-V also significantly improved the PASQ (P = 0.038) and the single PASQ questions, perspiration (P = 0.024), soft tissue swelling (P = 0.036), and overall health status (P = 0.035).
2 context sentences(design, population, supporting numbers)
Summary · context
The objective of the study was to assess whether weekly administration of 40 mg pegvisomant (PEG-V) improves quality of life (QoL) and metabolic parameters in acromegalic patients with normal age-adjusted IGF-I concentrations during long-acting somatostatin analog (SSA) treatment.
Summary · context
Twenty acromegalic subjects received either PEG-V or placebo for two consecutive treatment periods of 16 wk, separated by a washout period of 4 wk. Efficacy was assessed as change between baseline and end of each treatment period.
Report a problemFND-1864780605
06HumanNon-randomized trialEfficacy outcome
In acromegalic patients on SSA therapy, overall health status improved after pegvisomant addition (P = 0.035).
In plain wordsIn acromegalic patients on SSA therapy, overall health scores improved after pegvisomant addition compared with baseline.
Peptide
Pegvisomant
Outcome
Direction not reportedOverall health status
Study
n = 20
Comparator
Baseline on SSA therapy
Outcome group
Quality of life · Whole body
Studied dose
40 mg weekly · 16 wkAs given in this study (human).
Source sentences
Summary
The addition of PEG-V also significantly improved the PASQ (P = 0.038) and the single PASQ questions, perspiration (P = 0.024), soft tissue swelling (P = 0.036), and overall health status (P = 0.035).
2 context sentences(design, population, supporting numbers)
Summary · context
The objective of the study was to assess whether weekly administration of 40 mg pegvisomant (PEG-V) improves quality of life (QoL) and metabolic parameters in acromegalic patients with normal age-adjusted IGF-I concentrations during long-acting somatostatin analog (SSA) treatment.
Summary · context
Twenty acromegalic subjects received either PEG-V or placebo for two consecutive treatment periods of 16 wk, separated by a washout period of 4 wk. Efficacy was assessed as change between baseline and end of each treatment period.
Report a problemFND-1864780606
07HumanNon-randomized trialEfficacy outcome
In acromegalic patients on SSA therapy, IGF-I Z-score did not change significantly during pegvisomant addition (P = 0.34).
In plain wordsIn acromegalic patients on SSA therapy, IGF-I scores did not change significantly after pegvisomant addition compared with baseline.
Peptide
Pegvisomant
Outcome
No significant changeIGF-I Z-score
Study
n = 20
Comparator
Baseline on SSA therapy
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
40 mg weekly · 16 wkAs given in this study (human).
Source sentences
Summary
No significant change in Z-score of IGF-I (P = 0.34) was observed during addition of PEG-V.
2 context sentences(design, population, supporting numbers)
Summary · context
The objective of the study was to assess whether weekly administration of 40 mg pegvisomant (PEG-V) improves quality of life (QoL) and metabolic parameters in acromegalic patients with normal age-adjusted IGF-I concentrations during long-acting somatostatin analog (SSA) treatment.
Summary · context
Twenty acromegalic subjects received either PEG-V or placebo for two consecutive treatment periods of 16 wk, separated by a washout period of 4 wk. Efficacy was assessed as change between baseline and end of each treatment period.
Report a problemFND-1864780607

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:34 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.